LivaNova Stock Forecast, Price & News

+1.41 (+1.73 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $82.78
50-Day Range
MA: $77.24
52-Week Range
Now: $82.78
Volume302,054 shs
Average Volume494,533 shs
Market Capitalization$4.03 billion
P/E RatioN/A
Dividend YieldN/A
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LivaNova logo

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:LIVN
Year FoundedN/A



Sales & Book Value

Annual Sales$1.08 billion
Cash Flow$7.08 per share
Book Value$28.59 per share


Net Income$-155,180,000.00


Market Cap$4.03 billion
Next Earnings Date4/28/2021 (Confirmed)


Is LIVN Stock A Buy or Sell? - Yahoo Finance
April 14, 2021 |
Is LIVN Stock A Buy or Sell?
April 14, 2021 |
See More Headlines


Overall MarketRank

1.48 out of 5 stars

Medical Sector

547th out of 2,021 stocks

Electromedical Equipment Industry

12th out of 61 stocks

Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
+1.41 (+1.73 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

LivaNova (NASDAQ:LIVN) Frequently Asked Questions

Is LivaNova a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LivaNova stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View analyst ratings for LivaNova
or view top-rated stocks.

What stocks does MarketBeat like better than LivaNova?

Wall Street analysts have given LivaNova a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LivaNova wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting LivaNova?

LivaNova saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 2,530,000 shares, a decrease of 16.5% from the February 28th total of 3,030,000 shares. Based on an average daily volume of 506,500 shares, the days-to-cover ratio is presently 5.0 days.
View LivaNova's Short Interest

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for LivaNova

How can I listen to LivaNova's earnings call?

LivaNova will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday, February, 24th. The company reported $0.71 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.68 by $0.03. The firm had revenue of $269.60 million for the quarter, compared to analysts' expectations of $268.83 million. LivaNova had a positive trailing twelve-month return on equity of 5.55% and a negative net margin of 21.88%. LivaNova's revenue for the quarter was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.00 earnings per share.
View LivaNova's earnings history

How has LivaNova's stock been impacted by COVID-19?

LivaNova's stock was trading at $62.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LIVN shares have increased by 32.1% and is now trading at $82.78.
View which stocks have been most impacted by COVID-19

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $1.40-1.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98.

What price target have analysts set for LIVN?

6 brokers have issued 1-year price objectives for LivaNova's stock. Their forecasts range from $50.00 to $92.00. On average, they expect LivaNova's share price to reach $69.33 in the next year. This suggests that the stock has a possible downside of 16.2%.
View analysts' price targets for LivaNova
or view top-rated stocks among Wall Street analysts.

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 56, Pay $1.57M)
  • Ms. Keyna Pidcock Skeffington, Sr. VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $659.22k)
  • Mr. Alex Shvartsburg, Interim CFO and Corp. VP of Financial Planning, Analysis & International Region
  • Ms. Melissa Farina, VP of Investor Relations
  • Deanna Wilke, Director of Corp. Communications
  • Mr. Matthew Joseph Dodds III, Sr. VP of Corp. Devel.
  • Ms. Trui Hebbelinck, Chief HR Officer (Age 49)
  • Mr. Pritpal Shinmar, Sr. VP of Global Market Access (Age 64)
  • Dr. Bryan D. Olin, Sr. VP of Clinical, Quality Assurance & Regulatory Affairs (Age 54)
  • Mr. Paul R. Buckman, Pres of North America & GM of Transcatheter Mitral Valve Replacement (Age 65)

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova CEO Damien McDonald on Damien McDonald has an approval rating of 77% among LivaNova's employees.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a number of retail and institutional investors. Top institutional investors include Wedge Capital Management L L P NC (0.31%), Retirement Systems of Alabama (0.31%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, Thad Allen Huston and William A Kozy.
View institutional ownership trends for LivaNova

Which institutional investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, State of Alaska Department of Revenue, and Pacer Advisors Inc..
View insider buying and selling activity for LivaNova
or view top insider-selling stocks.

Which institutional investors are buying LivaNova stock?

LIVN stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, and Retirement Systems of Alabama. Company insiders that have bought LivaNova stock in the last two years include Alfred J Novak, and William A Kozy.
View insider buying and selling activity for LivaNova
or or view top insider-buying stocks.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $82.78.

How much money does LivaNova make?

LivaNova has a market capitalization of $4.03 billion and generates $1.08 billion in revenue each year. The company earns $-155,180,000.00 in net income (profit) each year or $3.08 on an earnings per share basis.

How many employees does LivaNova have?

LivaNova employs 4,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is

Where are LivaNova's headquarters?

LivaNova is headquartered at 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.